Rare Disease Trial, Recruiting NCT07075107 Sponsor: Assistance Publique Hopitaux De Marseille Condition: Rare Disease
Back to Rare Disease

Rare Disease Trial, Recruiting

NCT07075107
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You can be any gender, and any age from newborn to 99 years old
  • You (or your child) have been diagnosed with intellectual disability and/or low muscle tone (floppiness) that started in the newborn period, and are being seen at one of the three hospitals involved in this study
  • You (or your child's parent or guardian) have been told about the study and have agreed to take part by signing a consent form
  • Advanced genetic testing (such as a gene panel, exome, or genome test) has already been done but did not find a clear explanation for the symptoms
  • If the symptoms looked like Prader-Willi or Angelman syndrome: a specific chromosome 15 test came back negative
  • If the symptoms looked like Fragile X syndrome: a specific test for the FMR1 gene came back negative
  • If the symptoms looked like Myotonic Dystrophy type 1: a specific test for the DMPK gene came back negative
  • You (or your child) are covered by a French social security or health insurance scheme

Who may not be able to join:

  • People who are currently in prison or otherwise deprived of their freedom
  • Women who are pregnant or currently breastfeeding
  • The person who needs to sign the consent form does not understand French
  • People who are under legal guardianship or curatorship (a court-appointed legal protection arrangement)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 33491388499

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
9 March 2026
Est. completion
30 April 2029

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Patients with identified deleterious variant at RNA level

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov